Edition:
United States

Lannett Company Inc (LCI)

LCI on New York Consolidated

23.25USD
7 Dec 2016
Change (% chg)

$-1.20 (-4.91%)
Prev Close
$24.45
Open
$23.85
Day's High
$24.10
Day's Low
$22.38
Volume
1,206,579
Avg. Vol
1,150,386
52-wk High
$44.49
52-wk Low
$16.75

LCI

Chart for LCI

About

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June... (more)

Overall

Beta: 2.29
Market Cap(Mil.): $904.69
Shares Outstanding(Mil.): 37.00
Dividend: --
Yield (%): --

Financials

  LCI Industry Sector
P/E (TTM): -- 30.14 30.77
EPS (TTM): -0.49 -- --
ROI: -1.84 15.85 15.23
ROE: -3.46 16.96 16.56

BRIEF-Lannett announces approval for Metaxalone Tablets

* Lannett announces approval for Metaxalone Tablets USP, 800 mg

Nov 28 2016

BRIEF-Lannett announces approval for memantine hydrochloride tablets USP, 5 mg and 10 mg

* Lannett announces approval for memantine hydrochloride tablets usp, 5 mg and 10 mg

Nov 14 2016

BRIEF-James Flynn reports 5.43 pct passive stake in Lannett Company

* James flynn reports 5.43 percent passive stake in lannett company inc as of november 8 - sec filing Source text : http://bit.ly/2eFtqPg Further company coverage:

Nov 10 2016

BRIEF-Snow Capital Management reports 5.7 pct passive stake in Lannett Co

* Snow capital management lp reports 5.7 percent passive stake in lannett company inc as of october 6 - sec filing Source text : http://bit.ly/2ekC6zm Further company coverage:

Nov 09 2016

BRIEF-Lannett reports fiscal 2017 Q1 financial results

* Lannett Company Inc sees 2017 GAAP net sales $675 million to $685 million; down from $690 million to $700 million

Nov 03 2016

BRIEF-Lannett expects to report impairment charge related to methylphenidate of about $65 mln in results of operations for three months ended Sept 30

* Lannett-Concluded it expects to report impairment charge related to methylphenidate of about $65 million in results of operations for three months ended Sept 30 Source text: [http://bit.ly/2ffdfOg] Further company coverage:

Oct 28 2016

BRIEF-Lannett announces successful phase III clinical trial results for proprietary C-Topical product

* Lannett announces successful phase III clinical trial results for proprietary C-Topical product

Oct 27 2016

BRIEF-Lannett says to perform impairment analysis for value attributable to Methylphenidate intangible asset

* Says as a result of receiving FDA notice, will perform an impairment analysis for value attributable to Methylphenidate intangible asset Source text for Eikon: Further company coverage:

Oct 21 2016

BRIEF-Lannett seeks to withdraw approval of abbreviated NDA for methylphenidate hydrochloride extended release tablets

* Lannett comments on FDA proposal regarding methylphenidate extended release tablets

Oct 19 2016

BRIEF-Lannett announces approval for Buprenorphine and Naloxone Sublingual Tablets

* Received approval from FDA of ANDA for Buprenorphine and Naloxone Sublingual Tablets, 2 mg/0.5 mg and 8 mg/2 mg

Sep 20 2016

Competitors

  Price Chg
AbbVie Inc (ABBV.N) $59.99 -1.63
Pfizer Limited (PFIZ.NS) Rs1,850.85 -1.35
Dr.Reddy's Laboratories Ltd (REDY.NS) Rs3,183.80 -12.10

Earnings vs. Estimates